Publicaciones en colaboración con investigadores/as de Klinikum der Universität München (12)

2024

  1. ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 35, Núm. 3, pp. 248-266

  2. Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancer

    Bulletin du Cancer, Vol. 111, Núm. 3, pp. 277-284

2023

  1. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial

    Annals of Oncology, Vol. 34, Núm. 8, pp. 681-692

2022

  1. Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup

    The Lancet Oncology, Vol. 23, Núm. 8, pp. e374-e384

2020

  1. Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer

    International Journal of Cancer, Vol. 146, Núm. 2, pp. 439-448

2019

  1. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer

    New England Journal of Medicine, Vol. 381, Núm. 25, pp. 2416-2428

2018

  1. Intraoperative Electron Radiation Therapy Combined with External Beam Radiation Therapy after Gross Total Resection in Extremity Soft Tissue Sarcoma: A European Pooled Analysis

    Annals of Surgical Oncology, Vol. 25, Núm. 13, pp. 3833-3842

  2. Is there a role for HIPEC in ovarian cancer?

    Archives of Gynecology and Obstetrics

  3. Safety and dose modification for patients receiving niraparib

    Annals of Oncology, Vol. 29, Núm. 8, pp. 1784-1792

2017

  1. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials

    The Lancet Oncology, Vol. 18, Núm. 9, pp. 1159-1171

2006

  1. Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia

    Journal of the National Cancer Institute, Vol. 98, Núm. 4, pp. 273-284

1995

  1. Intraoperative strahlentherapie inklusive afterloadingverfahren in der gastrointestinalen chirurgie

    Viszeralmedizin: Gastrointestinal Medicine and Surgery, Vol. 11, Núm. 2, pp. 153-159